Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% 
How Braden Business Systems Use Auvik SaaS Management
to Identify, Secure, and Manage SaaS Sprawl About Braden Business Systems & Jon Fitzryk Since 1989, Braden Business Systems has...
Efficient Network Management: A Dive into Auvik Network Management’s Robust Features
In today's fast-paced digital world, efficient and effective network management has become more important than ever. With businesses relying heavily...
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction...
Gelatin Trick 2026 Warning: Does the Viral Gelatin Trick Recipe Actually Work? — Pink Gelatin Trick, Ice Gelatin Trick, Bariatric Jello, and Why Consumers Are Choosing Gelatine Sculpt Instead (New Investigation)
As interest in the gelatin trick surges in 2026, consumers across social platforms and search engines are asking whether the...
Steel Power Male Enhancement Claims Evaluated: Complete SteelPower Performance Report for Men
A 2026 report outlining Steel Power ingredient research, male enhancement supplement positioning, performance claim context, pricing structure, and what the...
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in...
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing...
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue...
Gelatide Drops Under Investigation: Full Gelatide-1 Consumer Report Reveals Shocking Hidden Risks & Fake Gelatin Trick Recipe
A 2026 informational consumer evaluation of Gelatide marketing claims, ingredient research context, Akkermansia muciniphila and proprietary blend dosage transparency, the...
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI...
SonusZen Claims Evaluated: Testing the Legitimacy of Sonus Zen Formulation for Hearing Support
A 2026 informational overview of the SonusZen hearing support formulation, Sonus Zen ingredient transparency and B vitamin research context, tinnitus...
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE...
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials,...
Press Release: AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST...
Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its...
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety...
New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting
Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness...
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World...
TheraWolf PainBalm and NeuroBalm Claims Evaluated: What Buyers Are Overlooking About Topical Relief Formulas, Ingredients, and Pricing in 2026
A 2026 consumer overview of TheraWolf PainBalm and NeuroBalm ingredient disclosures, topical magnesium balm research context, botanical pain relief cream...
Electronic Caregiver Introduces Hybrid Home Care – A Scalable Model Unlocking Millions of New Clients and Higher Margins
Electronic Caregiver is proud to sponsor the Synergy Home Care Annual Franchise Meeting LAS CRUCES, NM / ACCESS Newswire /...
NextPlat Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
HALLANDALE BEACH, Fla., March 27, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer...
Allergy & Asthma Network and Blue Marble Health Advance Digital Health Innovation with Evidence-Based Platform for Asthma Self-Management
Results of pilot testing demonstrate high usability and strong potential to expand equitable access to asthma self-management educationFAIRFAX, Va., March 27, 2026 /PRNewswire/ --...